Loading...
•
Sep 30, 2021
Marinus Pharmaceuticals Q3 2021 Earnings Report
Reported financial results and provided a business update.
Key Takeaways
Marinus Pharmaceuticals reported steady progress across its clinical programs and commercialization planning efforts in Q3 2021. The company aims to have ganaxolone commercially available in the U.S. and Europe by mid-2022, pending regulatory approvals.
Advanced ganaxolone across multiple indications with high unmet medical need in the U.S. and Europe.
European Medicines Agency accepted Marketing Authorization Application for review.
Prioritized second generation ganaxolone with a goal of beginning Phase 1 clinical trials early next year.
Planning a significant presence at the American Epilepsy Society’s 2021 Annual Meeting.
Forward Guidance
Marinus Pharmaceuticals is focused on advancing its clinical programs and preparing for the potential commercial launch of ganaxolone.
Positive Outlook
- Aiming for commercial availability of ganaxolone in the U.S. and Europe by mid-2022.
- Advancing ganaxolone across multiple indications.
- EMA accepted Marketing Authorization Application for review.
- Prioritizing second generation ganaxolone.
- Planning a significant presence at the American Epilepsy Society’s 2021 Annual Meeting.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...